NCF1 and experimental autoimmune encephalomyelitis: In accordance with these findings, NCF1 variants that reduce NOX2-derived ROS production in rat and mice have also been shown to promote multiple experimental autoimmune diseases, such as pristane-induced arthritis, experimental autoimmune encephalomyelitis, and SLE-like disease [23,24,25].